Research Analysts Issue Forecasts for ARTV FY2025 Earnings

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Cantor Fitzgerald dropped their FY2025 earnings per share estimates for shares of Artiva Biotherapeutics in a research report issued to clients and investors on Tuesday, March 25th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will post earnings per share of ($2.91) for the year, down from their previous estimate of ($2.72). Cantor Fitzgerald currently has a "Overweight" rating and a $20.00 target price on the stock. The consensus estimate for Artiva Biotherapeutics' current full-year earnings is ($4.95) per share.

Several other research firms also recently commented on ARTV. Wedbush reiterated an "outperform" rating and issued a $18.00 price target on shares of Artiva Biotherapeutics in a research report on Tuesday, March 25th. Needham & Company LLC reissued a "buy" rating and set a $23.00 target price on shares of Artiva Biotherapeutics in a research note on Tuesday, March 25th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $20.00 price objective on shares of Artiva Biotherapeutics in a report on Wednesday, March 26th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $20.40.

Artiva Biotherapeutics Stock Performance

Shares of ARTV stock traded up $0.01 during mid-day trading on Thursday, hitting $3.17. 18,952 shares of the stock were exchanged, compared to its average volume of 113,629. The stock's fifty day simple moving average is $4.71 and its two-hundred day simple moving average is $9.19. Artiva Biotherapeutics has a 12-month low of $3.02 and a 12-month high of $17.31.

Remove Ads

Institutional Trading of Artiva Biotherapeutics

Large investors have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. purchased a new stake in shares of Artiva Biotherapeutics in the 3rd quarter worth about $623,000. BNP Paribas Financial Markets purchased a new stake in shares of Artiva Biotherapeutics in the third quarter valued at about $42,000. MetLife Investment Management LLC acquired a new stake in shares of Artiva Biotherapeutics in the third quarter valued at approximately $135,000. Acuta Capital Partners LLC purchased a new position in shares of Artiva Biotherapeutics during the 3rd quarter worth approximately $680,000. Finally, RTW Investments LP acquired a new position in shares of Artiva Biotherapeutics during the 3rd quarter worth approximately $2,300,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.